Continuation and Switching of b/tsDMARD Therapy in a Cohort of 1,890 Japanese Patients with Rheumatoid Arthritis

This is the authors' abstract. We don't add key points for this paper.

Objective: The treatment of rheumatoid arthritis (RA) in Japan has evolved significantly since the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) in 2003. This study aimed to identify the key factors associated with poor drug continuation among patients with RA.